What’s Propelling BASILEA PHARMACEUTICA AG BASEL NAMEN-AKT (OTCMKTS:BPMUF) After Higher Shorts Reported?

May 18, 2018 - By Sophie Menendez

Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Logo

The stock of BASILEA PHARMACEUTICA AG BASEL NAMEN-AKT (OTCMKTS:BPMUF) registered an increase of 0.72% in short interest. BPMUF’s total short interest was 337,300 shares in May as published by FINRA. Its up 0.72% from 334,900 shares, reported previously. With 100 shares average volume, it will take short sellers 3373 days to cover their BPMUF’s short positions. The short interest to BASILEA PHARMACEUTICA AG BASEL NAMEN-AKT’s float is 3.12%.

It closed at $71.1325 lastly. It is down 0.00% since May 18, 2017 and is . It has underperformed by 11.55% the S&P500.

Basilea Pharmaceutica AG, together with its subsidiaries, operates as an integrated biopharmaceutical company. The company has market cap of $788.21 million. The firm focuses on the discovery, development, and commercialization of pharmaceutical products in the therapeutic areas of bacterial and fungal infections, and oncology. It currently has negative earnings. It offers isavuconazole, an intravenous and oral antifungal drug for the treatment of invasive mold infections under the name of CRESEMBA worldwide.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: